scholarly journals Paraoxonase gene mutations in amyotrophic lateral sclerosis

2010 ◽  
Vol 68 (1) ◽  
pp. 102-107 ◽  
Author(s):  
Nicola Ticozzi ◽  
Ashley Lyn LeClerc ◽  
Pamela J. Keagle ◽  
Jonathan D. Glass ◽  
Anne-Marie Wills ◽  
...  
2020 ◽  
Vol 9 (1) ◽  
pp. 261 ◽  
Author(s):  
Tereza Filipi ◽  
Zuzana Hermanova ◽  
Jana Tureckova ◽  
Ondrej Vanatko ◽  
Miroslava Anderova

Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease, which is characterized by the degeneration of motor neurons in the motor cortex and the spinal cord and subsequently by muscle atrophy. To date, numerous gene mutations have been linked to both sporadic and familial ALS, but the effort of many experimental groups to develop a suitable therapy has not, as of yet, proven successful. The original focus was on the degenerating motor neurons, when researchers tried to understand the pathological mechanisms that cause their slow death. However, it was soon discovered that ALS is a complicated and diverse pathology, where not only neurons, but also other cell types, play a crucial role via the so-called non-cell autonomous effect, which strongly deteriorates neuronal conditions. Subsequently, variable glia-based in vitro and in vivo models of ALS were established and used for brand-new experimental and clinical approaches. Such a shift towards glia soon bore its fruit in the form of several clinical studies, which more or less successfully tried to ward the unfavourable prognosis of ALS progression off. In this review, we aimed to summarize current knowledge regarding the involvement of each glial cell type in the progression of ALS, currently available treatments, and to provide an overview of diverse clinical trials covering pharmacological approaches, gene, and cell therapies.


2013 ◽  
Vol 47 (5) ◽  
pp. 751-757 ◽  
Author(s):  
E. V. Lysogorskaia ◽  
A. V. Rossokhin ◽  
N. Yu. Abramycheva ◽  
M. N. Zakharova ◽  
S. N. Illarioshkin

2006 ◽  
Vol 16 (11) ◽  
pp. 800-804 ◽  
Author(s):  
L. Corrado ◽  
S. D’Alfonso ◽  
L. Bergamaschi ◽  
L. Testa ◽  
M. Leone ◽  
...  

Aging ◽  
2020 ◽  
Author(s):  
Feng Wang ◽  
Shengyu Fu ◽  
Jianfan Lei ◽  
Hongchen Wu ◽  
Shugui Shi ◽  
...  

2004 ◽  
Vol 279 (44) ◽  
pp. 45951-45956 ◽  
Author(s):  
François Gros-Louis ◽  
Roxanne Larivière ◽  
Geneviève Gowing ◽  
Sandra Laurent ◽  
William Camu ◽  
...  

Peripherin is a neuronal intermediate filament associated with inclusion bodies in motor neurons of patients with amyotrophic lateral sclerosis (ALS). A possible peripherin involvement in ALS pathogenesis has been suggested based on studies with transgenic mouse overexpressors and with a toxic splicing variant of the mouse peripherin gene. However, the existence of peripherin gene mutations in human ALS has not yet been documented. Therefore, we screened for sequence variants of the peripherin gene (PRPH) in a cohort of ALS patients including familial and sporadic cases. We identified 18 polymorphic variants ofPRPHdetected in both ALS and age-matched control populations. Two additionalPRPHvariants were discovered in ALS cases but not in 380 control individuals. One variant consisted of a nucleotide insertion in intron 8 (PRPHIVS8–36insA), whereas the other one consisted of a 1-bp deletion within exon 1 (PRPH228delC), predicting a truncated peripherin species of 85 amino acids. Remarkably, expression of this frameshift peripherin mutant in SW13 cells resulted in disruption of neurofilament network assembly. These results suggest thatPRPHmutations may be responsible for a small percentage of ALS, cases and they provide further support of the view that neurofilament disorganization may contribute to pathogenesis.


2004 ◽  
Vol 74 (6) ◽  
pp. 1128-1135 ◽  
Author(s):  
Ying-Zhang Chen ◽  
Craig L. Bennett ◽  
Huy M. Huynh ◽  
Ian P. Blair ◽  
Imke Puls ◽  
...  

2010 ◽  
Vol 82 (5) ◽  
pp. 587-588 ◽  
Author(s):  
F. L. Conforti ◽  
W. Sproviero ◽  
I. L. Simone ◽  
R. Mazzei ◽  
P. Valentino ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document